EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Advancing Biopharmaceutical Innovation Through Cell Encapsulation and Biomimetic Therapeutic Systems
My interest in biopharmaceutical engineering began during my senior year as an undergraduate For my capstone project I worked on the encapsulation of...
Advisory Board
KNOWLEDGE BANK
-
Articles
Beyond the Chiral Blind Spot: Agentic AI and the Future of Stereochemistry-Aware Drug Discovery
Artificial intelligence AI is rapidly changing pharmaceutical research From target identification and literature analysis to molecular design and biological prediction AI is becoming an increasingly important research partner Generative AI has accelerated molecular ideation and expanded the chemical space scientists can explore
-
Techno Trends
FDA Authorises Aletta for Autonomous Blood Collection
The US Food and Drug Administration FDA has authorised Aletta the first standalone robotic device designed to collect blood from a patients arm without handson operator intervention
-
Projects
Cambrex Expands Milan R&D Operations With US$30 Million Investment
Cambrex has begun construction of a new research and development facility at its Profarmico Milano site in Italy supported by a US million investment The initiative is designed
-
Research Insights
Dipteran flight diversity is shaped by aerodynamic constraints, scaling, and evolutionary trade-offs
Flight has been a key innovation in insect evolution yet the selective and mechanistic pressures shaping their flight motor systems remain poorly understood Here we present a comprehensive comparative analysis of flight in Diptera true flies integrating morphology wingbeat kinematics
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
AI-Powered Clinical Data Management: Improving Quality, Speed, and Regulatory Compliance
Lakshmi
Clinical trial data volumes have roughly tripled while database lock timelines have lengthened, and headcount can no longer close that gap. This article examines how artificial intelligence is reshapi...
-
2
Revolutionizing Clinical Research: The Role of Energy-Efficient Trial Sites
Harry Callum
Eco-friendly trial sites are revolutionizing clinical research through their low energy use, low environmental footprint, and increased operating performance. These facilities reduce costs, enhance re...
-
3
AI Drug Discovery IP Strategy: Navigating Patent Challenges
Prof. (Dr.) Amrish Chandra
Artificial Intelligence is revolutionising drug discovery, offering unprecedented speed in target identification, compound optimisation, and clinical predictions. Yet, protecting these outputs through...
-
4
Role of Medical Affairs in HCP Engagement: Effective Strategies and Tools for Success
Kate Williamson
The changing healthcare ecosystem has enhanced the significance of Medical Affairs in achieving meaningful engagement of HCPs. In this article, the authors will discuss how strategic communication, di...
-
5
Formulation of sesamol loaded mannose surface conjugated smart lipid particles: Assessment of serum liver injury markers
Prashant Gurav
Manish Kumar Gupta
Vipul Sansare
Sesamol is a well-known antioxidant phyto constituent extracted from sesame oil. Numerous landmark investigations have reportedhydroxyl radical scavenging and the hepatoprotective potential of sesamol...
press releasesRead more...
DnaK Therapeutics & GATC Health Forge A Partnership To Evaluate, Accelerate & Prioritize Cancer Drug Candidates Using AI Platform
DnaK Therapeutics and GATC Health Corp jointly announced today a collaboration to use GATCs proprietary artificial intelligence platform to evaluate and prioritize innovative potential cancer drug candidates
Ono Pharma and Aitia Announce Collaboration to Identify Novel Drug Targets in Neurological Diseases
Aitia whose causal AIpowered Gemini Digital Twin Platform uniquely uncovers complex disease biology and applies that knowledge to pharmaceutical discovery and development and Ono Pharmaceutical Co
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Weave Bio the leader in AInative regulatory automation for drug development today announced a collaboration with Takeda to deploy the Weave platform across active programs in multiple global markets
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Professional snowboarder Chloe Kim is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attentiondeficithyperactivity disorder ADHD and her treatment plan with Qelbree
Events Read more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
09 - 10
Sep 2026iPSC Drug Development Summit
Hyatt Regency Boston Harbour,...
14 - 16
Sep 202614 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
15 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality
Illume Hotel Taipei, Taiwan
LATEST NEWSRead more...
Juniper Biosciences Receives FDA Breakthrough Therapy Designation for JBS-003
Juniper Biosciences has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for JBS Ffluoromisonidazole or FMISO a hypoxia tracer being developed to guide reduced radiation therapy in patients with HPVpositive oropharyngeal carcinoma OPC
FDA approves PharmaEssentia’s BESREMi for adults with essential thrombocythaemia
PharmaEssentia USA Corporation a subsidiary of PharmaEssentia Corporation has received approval from the US Food and Drug Administration FDA for BESREMi ropeginterferon alfabnjft to treat adults with essential thrombocythaemia ET a rare form of blood cancer
Transcat expands biomedical calibration business with Southeastern Biomedical acquisition
Transcat Inc has acquired privately held Southeastern Biomedical Associates Incorporated strengthening its biomedical calibration services and expanding its presence across the southeastern United States
FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer
The US Food and Drug Administration FDA has approved Revolution Medicines RASONQUE daraxonrasib tablets for adults with metastatic pancreatic adenocarcinoma PDAC who have received at least one previous systemic treatment or are not candidates for multiagent systemic therapy
U.S. FDA Approves Ziihera® Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
Zymeworks Inc has announced that its partner Jazz Pharmaceuticals has received approval from the US Food and Drug Administration FDA for two Ziihera zanidatamabhrii treatment regimens
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
BeOne Medicines has announced that the US Food and Drug Administration FDA has approved TEVIMBRA tislelizumab in combination with ZIIHERA zanidatamab and chemotherapy

